Drugs / HS-10370
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06963502 | May 2025 → Dec 2028 expected | colorectal cancer, non-small cell lung carcinoma | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06594874 | Oct 2024 → Oct 2026 expected | non-small cell lung carcinoma | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05367778 | Jun 2022 → Apr 2025 overdue | neoplasm | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07822542 | Oct 2026 → May 2030 expected | non-small cell lung carcinoma | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2026-09-16 | Jiangsu HengRui Medicine Co., Ltd. | Results 2026 WCLC｜恒瑞医药十余项肺癌领域研究亮相国际舞台 hengrui.com ↗
在54例疗效可评估患者中，初步ORR 87.0%，疾病控制率（DCR）98.1%。 |
| 2026-09-14 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Results WCLC 2026 | HANSOH PHARMA ANNOUNCES PROFFERED ORAL PRESENTATION OF PHASE I STUDY DATA OF HS-10370 COMBINED WITH ADEBRELIMAB AND CHEMOTHERAPY IN ADVANCED KRAS G12C-MUTATED NSCLC hspharm.com ↗
HS-10370 plus adebrelimab and chemotherapy demonstrated promising anti-tumor activity as first-line therapy for KRAS G12C-mutated advanced NSCLC, with a confirmed ORR of 81.5%; median PFS was not reached, and the 12-month PFS rate was 78.7%. |
| 2026-09-14 | Hansoh BioMedical R&D Company | Results WCLC 2026 | 翰森制药宣布HS-10370联合阿得贝利单抗及化疗用于KRAS G12C突变晚期NSCLC患者的 I 期研究数据入选口头报告 hansoh.cn ↗
中位随访13. 6个月后，确认的ORR为81. 5%，疾病控制率（DCR）达98. 1%，中位PFS尚未达到，12个月PFS率为78. 7%. |
| 2024-04-12 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Results 2024 AACR | HANSOH PHARMA PRESENTS CLINICAL DATA ON HS-10370 PHASE I STUDY AT AACR ANNUAL MEETING hspharm.com ↗
At this year's meeting, Hansoh Pharma released the results of the Phase I Study of HS-10370 monotherapy in a poster presentation. |
| 2024-04-10 | Hansoh BioMedical R&D Company | Results 2024 AACR | 翰森制药HS-10370 I期临床数据亮相国际学术大会 hansoh.cn ↗
翰 森 制 药 自 主 研 发 的 口 服 强 效、高 选 择 性 小 分 子KRAS G12C抑 制 剂（研 发 代 号：HS-10370）在 晚 期 实 体 瘤 中 的 单 药I期 临 床 研 究 结 果 以 壁 报 形 式 亮 相 本 届AACR年 会. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-09-16 | Jiangsu HengRui Medicine Co., Ltd. | 2026 WCLC｜恒瑞医药十余项肺癌领域研究亮相国际舞台 hengrui.com ↗ |
| 2026-09-14 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | WCLC 2026 | HANSOH PHARMA ANNOUNCES PROFFERED ORAL PRESENTATION OF PHASE I STUDY DATA OF HS-10370 COMBINED WITH ADEBRELIMAB AND CHEMOTHERAPY IN ADVANCED KRAS G12C-MUTATED NSCLC hspharm.com ↗ |
| 2026-09-14 | Hansoh BioMedical R&D Company | WCLC 2026 | 翰森制药宣布HS-10370联合阿得贝利单抗及化疗用于KRAS G12C突变晚期NSCLC患者的 I 期研究数据入选口头报告 hansoh.cn ↗ |
| 2024-04-12 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2024 AACR | HANSOH PHARMA PRESENTS CLINICAL DATA ON HS-10370 PHASE I STUDY AT AACR ANNUAL MEETING hspharm.com ↗ |
| 2024-04-10 | Hansoh BioMedical R&D Company | 2024 AACR | 翰森制药HS-10370 I期临床数据亮相国际学术大会 hansoh.cn ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-10370 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06963502 ↗ |
| Action | Inhibit | “inhibitor of KRAS G12C” NCT05367778 ↗ |
| Modality | Small molecule | “HS-10370 is an oral, highly selective, small molecular inhibitor of KRAS G12C.” NCT05367778 ↗ |
| Route | Oral | “HS-10370 will be administered orally once daily in a continuous regimen” NCT05367778 ↗ |
| Target | KRAS | “inhibitor of KRAS G12C” NCT05367778 ↗ |